Supplemental Figure 1

Statistical analysis plan.

- **Classification:**
  - dMMR vs. MSI comparison
    - Cohort: 70 ICI LOT with both biomarkers available
  - Assessment of differences between patients MSI-H and MSS
  - Assessment differences in outcomes: TTNT and TTD
  - Likelihood ratio test to compare MSI (NGS) vs. dMMR (IHC)
  - 1st Line ICI vs. Chemo
    - Cohort: 371 patients (28 ICI, 343 Chemo)
  - Assessment of differences between MSI-H on chemo vs. MSI-H on ICI vs. MSS on chemo vs. MSS on ICI
  - Prognostic Risk Score Generation among patients treated with chemo
  - Interaction term assessment between 1st line therapy and molecular biomarkers (MSI and TMB status)
  - MSI vs. TMB comparison
    - Cohort: 1,097 LOT with tissue specimens profiled with CGP
  - Assessment of TMB (continuous) by MSI status
  - Multivariable analysis of TMB prediction

- **Further Analysis:**
  - 1st Line ICI vs. Chemo Cohort: 371 patients (28 ICI, 343 Chemo)
  - Assessment differences in outcomes: TTNT and OS
  - Multivariable analysis of TMB prediction

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s).